@article{36a90e60e722498caf51e6cb2111bfd6,
title = "Patient-hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study",
abstract = "Background: Ensuring that patients with hematologic malignancies have an accurate understanding of their likelihood of cure is important for informed decision making. In a multicenter, longitudinal study, the authors examined discordance in patients' perception of their chance of cure versus that of their hematologists, whether patient-hematologist discordance changed after a consultation with a hematologist, and factors associated with persistent discordance. Methods: Before and after consultation with a hematologist, patients were asked about their perceived chance of cure (options were <10%, 10%-19%, and up to 90%-100% in 10% increments, and “do not wish to answer”). Hematologists were asked the same question after consultation. Discordance was defined as a difference in response by 2 levels. The McNemar test was used to compare changes in patient-hematologist prognostic discordance from before to after consultation. A generalized linear mixed model was used to examine associations between factors and postconsultation discordance, adjusting for clustering at the hematologist level. Results: A total of 209 patients and 46 hematologists from 4 sites were included in the current study. Before consultation, approximately 61% of dyads were discordant, which improved to 50% after consultation (P <.01). On multivariate analysis, lower educational level (",
keywords = "discordance, hematologic malignancies, perceived chance of cure, prognostic understanding",
author = "Loh, {Kah Poh} and Huiwen Xu and Anthony Back and Duberstein, {Paul R.} and {Gupta Mohile}, Supriya and Ronald Epstein and Colin McHugh and Klepin, {Heidi D.} and Gregory Abel and Lee, {Stephanie J.} and Areej El-Jawahri and LeBlanc, {Thomas W.}",
note = "Funding Information: Funded by the National Cancer Institute (grant CA098486 to Stephanie J. Lee). Funding Information: Kah Poh Loh was supported by the National Cancer Institute (grant K99CA237744) and Wilmot Research Fellowship and has acted as a paid consultant for Pfizer and Seattle Genetics for work performed outside of the current study. Supriya Gupta Mohile received a grant from Carevive Systems Inc for work performed outside?of the current study. Thomas W. LeBlanc has acted as a member of the advisory board for AbbVie, Amgen, Daiichi-Sankyo, Heron, and Medtronic; has acted as a paid consultant, member of the advisory board, and member of the Speakers' Bureau for Agios Pharmaceuticals; has acted as a paid consultant for and received research funding from AstraZeneca; has acted as a paid consultant for Carevive Systems Inc, Flatiron, Helsinn, and Pfizer; has received honoraria from Celgene; has acted as a paid consultant and member of the advisory board for Otsuka; has acted as a paid consultant for and received research funding from Seattle Genetics; has received royalties from UpToDate; has received personal fees from Welvie; and has received research funding from the American Cancer Society, Duke University, the National Institute of Nursing Research of the National Institutes of Health, and Jazz Pharmaceuticals for work performed outside of the current study. The other authors made no disclosures. Funded by the National Cancer Institute (grant CA098486 to Stephanie J. Lee). Funding Information: Kah Poh Loh was supported by the National Cancer Institute (grant K99CA237744) and Wilmot Research Fellowship and has acted as a paid consultant for Pfizer and Seattle Genetics for work performed outside of the current study. Supriya Gupta Mohile received a grant from Carevive Systems Inc for work performed outside of the current study. Thomas W. LeBlanc has acted as a member of the advisory board for AbbVie, Amgen, Daiichi‐Sankyo, Heron, and Medtronic; has acted as a paid consultant, member of the advisory board, and member of the Speakers' Bureau for Agios Pharmaceuticals; has acted as a paid consultant for and received research funding from AstraZeneca; has acted as a paid consultant for Carevive Systems Inc, Flatiron, Helsinn, and Pfizer; has received honoraria from Celgene; has acted as a paid consultant and member of the advisory board for Otsuka; has acted as a paid consultant for and received research funding from Seattle Genetics; has received royalties from UpToDate; has received personal fees from Welvie; and has received research funding from the American Cancer Society, Duke University, the National Institute of Nursing Research of the National Institutes of Health, and Jazz Pharmaceuticals for work performed outside of the current study. The other authors made no disclosures. Publisher Copyright: {\textcopyright} 2019 American Cancer Society",
year = "2020",
month = mar,
day = "15",
doi = "10.1002/cncr.32656",
language = "English (US)",
volume = "126",
pages = "1306--1314",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",
}